Boyu Capital is a private equity firm that invests in consumer, retail, media and technology, healthcare, and financial services sectors.
Business Model: B2C
Revenue: $5M
Employees: 11-50
Address: 88 Queensway
City: Hong Kong
State: other
Zip:
Country: HK
Boyu Capital Consultancy Co. Ltd is a private equity firm specializing in investments in China. Boyu Capital Consultancy Co. Ltd was founded on September 28, 2010 and is based in Hong Kong with an additional office in Beijing, China.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2021 | RecBio | Series C | 156.3M |
9/2017 | LifeMine Therapeutics | Series A | 0 |
9/2019 | Chengjia Apartment | Series A | 300M |
4/2021 | J&a;T Express | Private Equity Round | 2B |
12/2020 | SciNeuro | Series A | 100M |
11/2017 | Berry Oncology | Series A | 121.2M |
5/2013 | Berry Genomics | Series B | 14.7M |
8/2021 | MediTrust Health | Series C | 0 |
5/2018 | China Chengxin Credit | Series A | 0 |
10/2021 | WT Microtech Medical | Series E | 153M |
11/2021 | Positive Sequence Biology | Series A | 0 |
5/2018 | Brii Biosciences | Venture Round | 260M |
1/2019 | Yimidida | Series D | 266.1M |
3/2020 | Yuanfudao | Series G | 1B |
3/2020 | Pinduoduo | Post-IPO Equity | 1.1B |
6/2019 | Waterdrop | Series C | 144.6M |
4/2021 | Adcentrx Therapeutics | Series A | 50M |
9/2022 | Animoca Brands | Convertible Note | 110M |
9/2012 | Alibaba Group | Private Equity Round | 0 |
5/2018 | CStone Pharmaceuticals | Series B | 260M |
6/2014 | COFCO | Post-IPO Equity | - |
1/2021 | Lalamove | Series F | 1.5B |
1/2019 | Antengene Corporation | Series B | 0 |
3/2020 | Yatsen Holding | Series D | 240M |
6/2022 | Frontera Therapeutics | Series B | 0 |
1/2021 | 4Paradigm | Series D | 0 |
11/2021 | Edge Medical Robotics | Series C | 0 |
8/2021 | Abogen Biosciences | Series C | 0 |
6/2021 | ArriVent Biopharma | Series A | 81M |
2/2022 | ArriVent Biopharma | Series A | 69M |
12/2022 | ArriVent Biopharma | Series B | 0 |
11/2020 | D3 Bio | Series A | 200M |
2/2014 | LY.com | Series C | 82.3M |
12/2021 | Jinke | Post-IPO Equity | 478.6M |
6/2022 | Evat Master | Series A | 0 |
7/2016 | CStone Pharmaceuticals | Series A | 150M |
8/2018 | KLOOK | Series D | 200M |
12/2019 | Kuaishou Technology | Series F | 3B |
12/2021 | Recurrent.ai | Venture Round | 38M |
7/2020 | Antengene Corporation | Series C | 97M |
8/2021 | MediTrust Health | Series C | 308.3M |
8/2020 | Yuanfudao | Series G | 1.2B |
11/2018 | NetEase Cloud Music | Series B | 600M |
7/2018 | Trax | Series D | 0 |
11/2021 | Vision Medicals | Series D | 47M |
2/2018 | Viela Bio | Series A | 0 |
11/2021 | J&a;T Express | Private Equity Round | 0 |
2/2017 | iQiyi | Series G | 1.5B |
8/2021 | Zeekr | Series A | 500M |
7/2018 | Curon Biopharma | Series A | 150M |
7/2018 | MEGVII | Series D | - |
3/2022 | MoreSec | Series D | 0 |
5/2022 | Shuaike Pet Food Products | Private Equity Round | 0 |
9/2021 | XSKY Data Technology | Series E | 0 |
9/2018 | LianLian Pay | Venture Round | 146.6M |
8/2021 | Pulse Medical Technology | Series C | 0 |
1/2021 | KLOOK | Series E | 0 |
6/2022 | Frontera Therapeutics | Series B | 0 |
6/2022 | Evat Master | Series A | 0 |
5/2022 | Shuaike Pet Food Products | Private Equity Round | 0 |
3/2022 | MoreSec | Series D | 0 |
2/2022 | ArriVent Biopharma | Series A | 0 |
12/2021 | Recurrent.ai | Venture Round | 0 |
12/2021 | Jinke | Post-IPO Equity | 0 |
11/2021 | Vision Medicals | Series D | 0 |
11/2021 | J&a;T Express | Private Equity Round | 0 |
11/2021 | Positive Sequence Biology | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|